Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What neoadjuvant treatment strategy would you use for an unresectable intrahepatic cholangiocarcinoma with dMMR with the goal of downstaging to achieve surgical resectability?
Patient with ECOG 0-1
Related Questions
What factors (age, PS) do you consider to avoid using FLOT in the perioperative treatment of gastric and esophageal cancers?
Is there a role for chemotherapy for asymptomatic Well-Differentiated Papillary Mesothelioma or Multicystic mesothelioma?
Which chemotherapy would you recommend for concurrent use with radiation in a patient with localized esophageal adenocarcinoma who has severe Charcot-Marie-Tooth disease?
How would you approach treatment of a patient with adenocarcinoma of unknown primary only found in a left supraclavicular lymph node?
Do you give adjuvant chemotherapy for an incidental cholangiocarcinoma found at time of liver transplant (done for HCC or other reason) in the explanted liver?
Do you offer adjuvant chemotherapy to patients with rectal cancer who were on Watch-and-Wait, had local recurrence and underwent resection?
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
Which patients with metastatic HER2 negative, PD-L1 <1% esophageal cancer patients, would you utilize paclitaxel/ramucirumab maintenance?
How does the management of POLE mutated colorectal cancer differ from that of dMMR/MSI high disease?
How would you treat an MMR-proficient T2 N0 low-rectal cancer (measuring 2 cm extending 4-6 cm from the anal verge) in a patient who wishes to preserve his sphincter?